Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 4/20 | 0.72 |
| ▸ | CPA3 | P15088 | 3/20 | 0.72 |
| ▸ | CPB1 | P15086 | 1/20 | 0.72 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.72 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17537907 | 0.92 | CPA1 (0.84) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL10436391 | 0.88 | CYP1A2 (0.68) | CPA1CPA3CPB1CPB2SLC7A5 | |
| SCHEMBL12528500 | 0.84 | SLC7A5 (0.60) | CPA1CPA3CPB1CPB2SLC7A5 | |
| SCHEMBL393002 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL1915564 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL5688996 | 0.84 | CPA1 (1.00) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL12494638 | 0.84 | SLC7A5 (0.60) | CPA1CPA3CPB1CPB2SLC7A5 | |
| SCHEMBL9306070 | 0.83 | CPA1 (0.70) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL2533621 | 0.83 | CPA1 (0.70) | CPA1CPA3CPB1CPB2FOLH1 | |
| SCHEMBL17693395 | 0.83 | CPA1 (0.70) | CPA1CPA3CPB1CPB2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491117-B2 | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity | Sorbonne Université (FR) | 2022-11-08 | — | — | US | claimed |
| US-20200253889-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE RELATED CONDITIONS AND OBESITY. | Sorbonne Université (FR) | 2020-08-13 | — | — | US | claimed |
| EP-3691624-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE RELATED CONDITIONS AND OBESITY. | Sorbonne Université (FR) | 2020-08-12 | — | — | EP | claimed |
| CN-111386106-A | Compounds for the prevention and treatment of disorders associated with glucose intolerance and obesity | 索邦大学 | 2020-07-07 | — | — | CN | claimed |
| WO-2019068788-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE RELATED CONDITIONS AND OBESITY. | Sorbonne Université (FR) | 2019-04-11 | — | — | WO | claimed |
| EP-3466417-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE RELATED CONDITIONS AND OBESITY | Sorbonne Université (FR) | 2019-04-10 | — | — | EP | claimed |
| US-11491117-B2 | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity | Sorbonne Université (FR) | 2022-11-08 | — | — | US | disclosed |
| US-20200253889-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE RELATED CONDITIONS AND OBESITY. | Sorbonne Université (FR) | 2020-08-13 | — | — | US | disclosed |
| CN-111386106-A | Compounds for the prevention and treatment of disorders associated with glucose intolerance and obesity | 索邦大学 | 2020-07-07 | — | — | CN | disclosed |
| EP-3466417-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE RELATED CONDITIONS AND OBESITY | Sorbonne Université (FR) | 2019-04-10 | — | — | EP | disclosed |
| US-20100035309-A1 | ANALYSIS AND ENHANCEMENT OF METABOLIC PATHWAYS FOR METHANOGENESIS | LUCA TECHNOLOGIES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491117-B2 | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity | GPR119, GYS2, PYGL | CPA1 2063/4885CPA3 2325/4885CPB1 1272/4885 |
| US-20200253889-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE RELATED CONDITIONS AND OBESITY. | GPR119, CPT1A, GYS2 | CPA1 1856/4885CPA3 2148/4885CPB1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.